Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer.

Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, Lee JJ, Schuchter LM, Xu X, Herlyn M, Marmorstein R, Gimotty PA, Speicher DW, Winkler JD, Amaravadi RK.

Cancer Discov. 2018 Nov 15. pii: CD-18-0706. doi: 10.1158/2159-8290.CD-18-0706. [Epub ahead of print]

PMID:
30442709
2.

Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis.

Ecker BL, Kaur A, Douglass SM, Webster MR, Almeida FV, Marino GE, Sinnamon AJ, Neuwirth MG, Alicea GM, Ndoye A, Fane M, Xu X, Sim MS, Deutsch GB, Faries MB, Karakousis GC, Weeraratna AT.

Cancer Discov. 2019 Jan;9(1):82-95. doi: 10.1158/2159-8290.CD-18-0168. Epub 2018 Oct 2.

PMID:
30279172
3.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

PMID:
29898988
4.

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.

Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, Levi SM, Wei Z, Barber-Rotenberg JS, Murphy ME, Mills GB, Lu Y, Rabinowitz J, Marmorstein R, Liu Q, Liu S, Xu X, Herlyn M, Zoncu R, Brady DC, Speicher DW, Winkler JD, Amaravadi RK.

Cancer Discov. 2017 Nov;7(11):1266-1283. doi: 10.1158/2159-8290.CD-17-0741. Epub 2017 Sep 12.

5.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT.

Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.

6.

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. doi: 10.1111/pcmr.12303. Epub 2014 Sep 1.

Supplemental Content

Loading ...
Support Center